Corcept shares halved on mifepristone failure in depression
Corcept Therapeutics saw its stock price cut in half after the company revealed in its first quarter earnings report that mifepristone failed to achieve the primary endpoint in a Phase III clinical trial for the treatment of psychotic depression.